Re-programming microbes to fight cancer — turning our evolutionary enemies into life-saving allies.

Dual-action live biotherapeutics:

Our proprietary engineered microbe knocks out tumour-feeding hormones and delivers targeted immune stimulation cytokines: all in one oral dose. A smarter, patient-friendly approach that cuts treatment costs while amplifying anti-cancer power.

Why it matters

  • Science-first roadmap

    Backed by peer-reviewed microbial engineering, proof-of-concept studies are underway with a clear path toward preclinical and first-in-human clinical trials.

  • Oral & self-replicating

    A single capsule seeds a living factory in the gut—no infusions, no cold-chain, manageable by antibiotics, dramatically lower treatment cost.

  • Two-pronged attack

    Simultaneously depletes tumour-fueling hormones and delivers immune-activating cytokines for a synergy no single drug can match.

How it works

Targeted delivery

Once settled, the microbe multiplies, enzymatically converts excess androgens into inert metabolites, and continuously secretes a long-acting immune-activating cytokine. Growth can be boosted by probiotic co-feeding or shut down within 48 h using an off-the-shelf oral antibiotic.

On-site biotransformation

A gastric-resistant, pH-triggered capsule ferries the living drug safely through the stomach and dissolves in the lower intestine, releasing billions of viable cells exactly where they can engraft, operate — and later be tuned with simple dietary probiotics.

Dual strike on cancer

Falling hormone levels starve androgen-sensitive tumours while the cytokine signal re-energises cytotoxic T-cells, creating a one-two punch that also synergises with checkpoint inhibitors — all under clinician control thanks to the antibiotic “kill-switch.”

Pipeline & Milestones

Partner & Investor Call

Elpida BioPharm is seeking seed-stage collaborators and investors to propel lead program EL-202 toward first-in-human studies and expand our dual-action live-biotherapeutic platform. We welcome visionary investors and strategic allies across oncology, microbiome science, and advanced drug-delivery.